WP
FATE icon

Woodline Partners’s Fate Therapeutics FATE Stock Holding History

Woodline Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Sell
159,650
-79,000
-33% -$146K ﹤0.01% 976
2026
Q1 		$286K Sell
238,650
-118,000
-33% -$144K ﹤0.01% 1008
2025
Q4 		$350K Sell
356,650
-356,000
-50% -$427K ﹤0.01% 944
2025
Q3 		$898K Hold
712,650
– – ﹤0.01% 809
2025
Q2 		$798K Sell
712,650
-711,517
-50% -$827K ﹤0.01% 824
2025
Q1 		$1.13M Buy
1,424,167
+1,382
+0.1% +$1.69K 0.01% 755
2024
Q4 		$2.35M Sell
1,422,785
-1,642,962
-54% -$4.14M 0.02% 630
2024
Q3 		$10.7M Buy
3,065,747
+2,063,745
+206% +$8.03M 0.09% 281
2024
Q2 		$3.29M Sell
1,002,002
-890,000
-47% -$3.9M 0.03% 378
2024
Q1 		$13.9M Buy
1,892,002
+1,506,638
+391% +$9.33M 0.13% 218
2023
Q4 		$1.44M Buy
+385,364
New +$910K 0.02% 393
2023
Q3 		– Sell
-100,056
Closed -$476K – 637
2023
Q2 		$476K Buy
100,056
+52
+0.1% +$287 0.01% 547
2023
Q1 		$570K Sell
100,004
-60,714
-38% -$366K 0.01% 519
2022
Q4 		$1.62M Hold
160,718
– – 0.02% 498
2022
Q3 		$3.6M Hold
160,718
– – 0.05% 355
2022
Q2 		$3.98M Hold
160,718
– – 0.06% 291
2022
Q1 		$6.23M Sell
160,718
-38,358
-19% -$1.49M 0.1% 222
2021
Q4 		$11.6M Buy
199,076
+46,119
+30% +$2.61M 0.17% 168
2021
Q3 		$9.07M Buy
152,957
+21,851
+17% +$1.71M 0.15% 175
2021
Q2 		$11.4M Buy
131,106
+4,746
+4% +$382K 0.21% 120
2021
Q1 		$10.4M Buy
+126,360
New +$12.1M 0.23% 114

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners's FATE Position: Q2 2026 in Review

Woodline Partners reduced its Fate Therapeutics (FATE) stake by 33% in Q2 2026, selling an estimated $146K and leaving 159,650 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Woodline Partners first reported a position in FATE in Q1 2021 and has held it in 21 quarters since. The position peaked at $13.9M in Q1 2024. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Woodline Partners held 159,650 shares of Fate Therapeutics worth $431K as of Q2 2026.
  • Woodline Partners sold 79,000 Fate Therapeutics shares in Q2 2026, an estimated $146K.
  • Fate Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #976 holding.
  • Woodline Partners first reported a position in Fate Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Woodline Partners's Fate Therapeutics position peaked at $13.9M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.